CPRX
Catalyst Pharmaceuticals, Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website catalystpharma.com
- Employees(FY) 82
- ISIN US14888U1016
Performance
+5.37%
1W
+6.11%
1M
+17.79%
3M
+23.24%
6M
-1.9%
YTD
+31.6%
1Y
Profile
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Investment Analysis Report: CPRX
Overview
In this investment analysis report, we will delve into a comprehensive evaluation of the pharmaceutical company CPRX. We will analyze the company's financial health, earnings and revenue growth, profitability, operating margin, operating cash flow, capital expenditure trends, and efficiency. By examining...
Technical Analysis of CPRX 2024-05-10
Overview:
In analyzing the technical indicators for CPRX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key factors, we aim to offer valuable insights and predictions for the upcoming days.
Trend Indicators...
Recent News & Updates
- 2024-05-15 08:00
- 2024-05-10 05:20
- 2024-05-08 23:40
- 2024-05-08 17:04
Catalyst: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-08 16:16
- 2024-05-08 04:16
- 2024-05-02 10:01
- 2024-05-01 10:01
- 2024-05-01 08:00
- 2024-04-30 22:01
- 2024-04-30 20:00
- 2024-04-24 13:45
- 2024-04-24 13:00
- 2024-04-23 20:00
CPRX: Lowering target price to $15.00(Argus Research)
- 2024-04-22 08:00
- 2024-04-21 20:00
- 2024-04-18 10:49
- 2024-04-13 12:18
Jim Cramer’s 10 Favorite Healthcare Stock Picks in 2024(Insider Monkey)
- 2024-04-13 00:18
Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024(Insidermonkey)
- 2024-03-29 11:30
- 2024-03-28 23:30
- 2024-03-28 08:03
- 2024-03-27 20:03
- 2024-03-27 08:03
- 2024-03-27 07:44
- 2024-03-26 20:03
- 2024-03-22 10:00
- 2024-03-20 05:14
- 2024-03-18 20:01
7 Biotech Stocks Ready to Ride the Sector’s Resurgence(InvestorPlace)
- 2024-03-13 14:00
Page 1 of 6
previousnext